S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?

References

• Kish J, Drelichman A, Jacobs J et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat. Rep.66(3), 471–474 (1982).
   PubMedGoogle Scholar
• Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope98(11), 1205–1211 (1988).
   PubMed Web of Science ®Google Scholar
• Vokes EE, Mick R, Lester EP, Panje WR, Weichselbaum RR. Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J. Clin. Oncol.9(8), 1376–1384 (1991).
   PubMedGoogle Scholar
• Choksi AJ, Hong WK, Dimery IW, James P, Guillamondegui OM, Byers RM. Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma. Cancer61(5), 909–912 (1988).
   PubMed Web of Science ®Google Scholar
• O’Brien M, Schofield JB, Lorentzos A et al. The use of cisplatin plus 5-fluorouracil chemotherapy in an unselected group of patients with recurrent squamous cell carcinoma of the head and neck. Eur. J. Cancer B Oral Oncol.30B(4), 265–267 (1994).
   PubMedGoogle Scholar
• Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol.5(6), 521–526 (1994).
   PubMed Web of Science ®Google Scholar
• Paccagnella A, Pappagallo GL, Segati R et al. Response and toxicity of cisplatin and 120-h 5-fluorouracil infusion in pretreated and untreated patients with advanced epidermoid cancer of the head and neck. Am. J. Clin. Oncol.13(3), 194–198 (1990).
   PubMedGoogle Scholar
• Shirasaka T, Shimamato Y, Ohshimo H et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs7(5), 548–557 (1996).
   PubMed Web of Science ®Google Scholar
• Tatsumi K, Fukushima M, Shirasaka T, Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res.78(7), 748–755 (1987).
   PubMedGoogle Scholar
• Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res.53(17), 4004–4009 (1993).
   PubMed Web of Science ®Google Scholar
• Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M. Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int. J. Mol. Med.22(6), 709–716 (2008).
   PubMedGoogle Scholar
• Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late Phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur. J. Cancer34(11), 1715–1720 (1998).
   PubMed Web of Science ®Google Scholar
• Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology58(3), 191–197 (2000).
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Baba H, Sakata Y et al. Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br. J. Cancer83(2), 141–145 (2000).
   PubMed Web of Science ®Google Scholar
• Okusaka T, Funakoshi A, Furuse J et al. A late Phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother. Pharmacol.61(4), 615–621 (2008).
   PubMed Web of Science ®Google Scholar
• Kawahara M, Furuse K, Segawa Y et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br. J. Cancer85(7), 939–943 (2001).
   PubMed Web of Science ®Google Scholar
• Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Early Phase II study of S-1 in patients with advanced head and neck cancer. S-1 Cooperative Study Group (Head and Neck Working Group)]. Gan. To. Kagaku. Ryoho.25(8), 1151–1158 (1998).
   PubMedGoogle Scholar
• Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B. [Late Phase II study of S-1 in patients with advanced head and neck cancer]. Gan. To. Kagaku. Ryoho.28(10), 1381–1390 (2001).
   PubMedGoogle Scholar
• Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol.9(3), 215–221 (2008).
   PubMed Web of Science ®Google Scholar
• Ajani JA, Faust J, Ikeda K et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol.23(28), 6957–6965 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JL, Kang HJ, Kang YK et al. Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother. Pharmacol.61(5), 837–845 (2008).
   PubMedGoogle Scholar
• Sato Y, Kondo H, Honda K et al. A Phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer: 2-week S-1 administration regimen. Int. J. Clin. Oncol.10(1), 40–44 (2005).
   PubMedGoogle Scholar
• Choi YJ, Chung JS, Shin HJ et al. Induction chemotherapy with S-1 plus cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. J. Laryngol. Otol.122(8), 848–853 (2008).
   PubMedGoogle Scholar
• Watanabe A, Taniguchi M, Yamashita T et al. Phase I/II study of S-1 combined with carboplatin in recurrent and/or metastatic head and neck cancer as outpatient chemotherapy. Head Neck28(7), 620–625 (2006).
   PubMedGoogle Scholar
• Kodaira T, Fuwa N, Tachibana H, Hidano S. Phase I study of S-1 and nedaplatin for patients with recurrence of head and neck cancer. AntiCancer Res.26(3B), 2265–2268 (2006).
   PubMedGoogle Scholar
• Fujii M, Tomita K, Nishijima W et al. Phase I/II study of S-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn. J. Clin. Oncol.40(3), 214–221 (2010).
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357(17), 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357(17), 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. Clin. Oncol.23(34), 8636–8645 (2005).
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised Phase III noninferiority trial. Ann. Oncol.20(4), 666–673 (2009).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359(11), 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar